H.C. Wainwright Assumes Aprea (APRE) at Buy

H.C. Wainwright analyst Joseph Pantginis assumes coverage on Aprea (NASDAQ: APRE) with a Buy rating and a price target of $3.00.

The analyst commented, "We are assuming coverage of Aprea with a Buy rating and $3 price target. Aprea has embarked upon a renewed journey after a significant clinical setback with eprenetapopt (APR-246), and announced the acquisition of privately held Atrin Pharmaceuticals in May 2022. The acquired assets and technology from Atrin are now the key focus of Aprea's investment case and is based on targeting the ATR pathway (ataxia telangiectasia and Rad3-related), which limit a tumor cell's ability to engage DNA damage and response pathways (DDR); the overall approach by Aprea is targeting synthetic lethality to exploit genetically compensatory pathways, which could significantly reduce a tumor cell's ability to become resistant to treatment. We are excited by the new story at Aprea, but do highlight the overall risk of being at the starting point of clinical development for its lead asset, ATR-119; this early stage, at this point, may keep certain investors on the sidelines ahead of initial clinical readouts; however, we believe the scientific rationale and preclinical data are sound allowing for thoughtful development."

For an analyst ratings summary and ratings history on Aprea click here. For more ratings news on Aprea click here.

Shares of Aprea closed at $0.68 yesterday.

You May Also Be Interested In